Accelerating Genomic Biomarker Translation

Cancer patients’ need innovative medicines more than ever, and they require personalised therapies specific to their unique biology fast. Together, international partners such as Illumina and Almac can get pharmaceutical pipelines ready quickly for global oncology clinical trials.

Utilising comprehensive genomic panels that can test for multiple biomarkers at the same time, whilst maximising clinical trial data from one patient sample, is key to delivering these solutions at speed.

Illumina discuss how they can gain speed in clinical development by avoiding bridging studies while Almac demonstrate how we deliver diagnostic testing utilising cutting edge genomic panels & providing tailored support at clinical sites through our global footprint of CLIA and CAP certified laboratories.

Webinar presenters:

Matt Nelson

Senior Director, Companion Diagnostic (CDx) Partnering, Illumina

Dr Leeona Galligan

VP of UK Operations, Almac

Shared with kind permission from Illumina